Cold agglutinin disease revisited: a multinational, observational study of 232 patients

Sigbjørn Berentsen, Wilma Barcellini, Shirley D'Sa, Ulla Randen, Tor Henrik Anderson Tvedt, Bruno Fattizzo, Einar Haukås, Megan Kell, Robert Brudevold, Anders E.A. Dahm, Jakob Dalgaard, Hege Frøen, Randi Fykse Hallstensen, Pernille H. Jæger, Henrik Hjorth-Hansen, Agnieszka Małecka, Markku Oksman, Jürgen Rolke, Mallika Sekhar, Jon Hjalmar SørbøEirik Tjønnfjord, Galina Tsykunova, Geir E. Tjønnfjord

Research output: Contribution to journalArticle

Abstract

We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in 5 countries. In Norway and a northern region of Italy, the study was close to being population-based. For the first time, we demonstrate fourfold differences between cold and warmer climates regarding prevalence (20 vs 5 cases/million) and incidence (1.9 vs 0.48 cases/million per year). Mean baseline hemoglobin level was 9.3 g/dL, but 27% had hemoglobin <8 g/dL. Identification of typical features of CAD-associated lymphoproliferative disorder in the bone marrow was greatly increased by centralized biopsy assessment. CAD seems to be associated with a slightly increased risk of venous thrombosis. This work includes a follow-up study of therapies, focusing on the long-term outcomes of the rituximab plus bendamustine and rituximab plus fludarabine regimens. Rituximab plus bendamustine therapy resulted in responses in 35 (78%) of 45 patients; 24 (53%) achieved complete response. Interestingly, these rates were still higher than observed in the original (2017) prospective trial, and we also found a shift toward deeper responses with time. This is explained by the prolonged time to response seen in many patients, probably related to long-lived plasma cells. In patients responding to rituximab-bendamustine, median response duration was not reached after 88 months, and estimated 5-year sustained remission was 77%. The regimen appeared safe regarding late-occurring malignancies. Rituximab plus fludarabine therapy seems to carry a higher risk of long-term adverse effects.

Original languageEnglish
Pages (from-to)480-488
Number of pages9
JournalBlood
Volume136
Issue number4
DOIs
Publication statusPublished - Jul 23 2020

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Cold agglutinin disease revisited: a multinational, observational study of 232 patients'. Together they form a unique fingerprint.

  • Cite this

    Berentsen, S., Barcellini, W., D'Sa, S., Randen, U., Tvedt, T. H. A., Fattizzo, B., Haukås, E., Kell, M., Brudevold, R., Dahm, A. E. A., Dalgaard, J., Frøen, H., Hallstensen, R. F., Jæger, P. H., Hjorth-Hansen, H., Małecka, A., Oksman, M., Rolke, J., Sekhar, M., ... Tjønnfjord, G. E. (2020). Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood, 136(4), 480-488. https://doi.org/10.1182/blood.2020005674